anti-NEK2 (NEK2) Antikörper

Mouse (Murine) NIMA (Never in Mitosis Gene A)-Related Kinase 2 (NEK2) Interaktionspartner

1. Cep85 is a bona fide Nek2A-binding partner that surrounds the proximal ends of centrioles where it cooperates with PP1gamma (also known as PPP1CC) to antagonize Nek2A

2. The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis.

3. Nek2 transgenic mice develop spontaneous germinal centers and exhibit an enhanced T cell dependent immune response our data demonstrates a novel role for Nek2 in regulating B cell development and the immune response

4. these data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease.

5. CIP2A strongly interacts with NEK2 during G2/M phase, thereby enhancing NEK2 kinase activity to facilitate centrosome separation in a PP1- and PP2A-independent manner.

6. Nek2 and its substrate, centrobin/Nip2, are required for proper meiotic spindle formation of the mouse oocytes

7. Data show that NEK2 was identified as a tumor-associated antigen.

8. Nek2 may be a mitotic regulator that is involved in diverse cell cycle events.

9. Tcp10 promoter-directed expression of the Nek2 gene in mouse meiotic spermatocytes.

10. The MAPK pathway triggers activation of Nek2 during chromosome condensation in mouse spermatocytes.

11. Functional interaction between HMGA2 and Nek2 plays a crucial role in the correct process of chromatin condensation in meiosis

12. These results propose a possible involvement of Nek2 in biological processes of the Golgi body, perhaps in relation to the inheritance of Golgi during mitosis or to cell cycle stage-specific regulation of exocytosis.

13. importance of Nek2 for proper chromosome segregation in embryonic mitoses.

14. identified mouse Telomeric Repeat Binding Factor 1 (Trf1) as a protein that interacts directly with the spindle checkpoint protein Mad1 and the mitotic kinase Nek2

15. The phenotypic similarities of the Nip2/centrobin- and Nek2-suppressed embryos suggest that Nip2/centrobin may be a substrate of Nek2 that is required for mitotic spindle assembly in early mouse embryos.

Human NIMA (Never in Mitosis Gene A)-Related Kinase 2 (NEK2) Interaktionspartner

1. Controlling the dynamics of the Nek2 leucine zipper by engineering of "kinetic" disulphide bonds.

2. Newly diagnosed myeloma patients with activated NF-kappaB signaling through increased NEK2 activity had poorer event-free and overall survivals based on multiple independent clinical cohorts.

3. Study provide new evidence to suggest that CUG2 overexpression contributes to tumor formation through NEK2/beta-catenin signaling by enhancing the phosphorylation of betacatenin at Ser33/Ser37 by activating NEK2, thus stabilizing betacatenin.

4. NEK2 plays a significant role in cell cycle progression in hepatocellular carcinoma, promotes metastasis and is associated with high recurrence risk after hepatectomy.

5. Elevated NEK2, DLGAP5 and ECT2 expression was negatively correlated with both overall survival (OS) and relapse-free survival (RFS).

6. We identified 16 potentially druggable candidates. Among them, NEK2, BIRC5, and TOP2A were also found to be amplified in breast cancer, suggesting that they could act as strategic players in the obese-deregulated transcriptome.

7. High NEK2 expression is a risk factor for poor survival in Hepatocellular Carcinoma patients.

8. Taken together with the result that gamma-taxilin protein expression levels were decreased at the onset of mitosis, we propose that gamma-taxilin participates in Nek2A-mediated centrosome disjunction as a negative regulator through its interaction with Nek2A.

9. NEK2 can promote HCC metastasis through induction of the epithelial-mesenchymal transition.

10. evaluated the role of NEK2 in bone destruction of MM via clinical gene expression profiling data analysis and in vitro and in vivo mouse models. Further, treatment with the heparanase inhibitor Roneparstat, a Phase 1 drug in MM treatment,14 markedly inhibited OCL differentiation and rescued bone mass loss induced by NEK2 overexpression, suggesting that targeting NEK2 and/or its signaling pathway may be not only for preven

11. Nek2 is able to individually shorten cilia when cilia are growing but requires interaction with Aurora A when cilia are being absorbed. PP1 binding protein, PPP1R42, directly inhibits Nek2 and increases cilia formation.

12. Data suggest that low NIMA-related kinase 2 (NEK2) expression might be a useful predictor in hepatocellular carcinoma (HCC) as a poor prognostic factor, and could serve as a potential therapeutic target for HCC.

13. present study firstly reveals that NEK2 protein is widely overexpressed in gliomas. NEK2 overexpression correlates significantly with malignancy (WHO grades), proliferation (Ki-67) and prognosis in malignant gliomas

14. Results found NEK2 to be upregulated in lung cancer tissues and, its 3'-UTR mRNA is directly targeted by miR-128 to regulate its protein expression.

15. Displacement of Dishevelled (DVL) from the centrosome and its release into the cytoplasm on NEK2 phosphorylation is coupled to the removal of linker proteins.

16. NEK2 promotes aerobic glycolysis through regulating splicing of PKM and increasing the PKM2/PKM1 ratio in myeloma cells which contributes to its oncogenic activity.

17. Nek2A is found to stabilize SuFu at least partly depending on its kinase activity, thereby triggering phosphorylation of the SuFu protein.

18. NEK2 has a role in maintaining glioma stem cells in glioblastoma by stabilizing the EZH2 protein

19. This study reports a novel set of Dengue virus (DENV) NS1-interacting host cell proteins in the HepG2 cell line and proposes possible roles for human NEK2, TAO1, and COG1 in DENV infection.

20. Our findings suggested that NIMA-related kinase 2B could play a role in the development and progression of breast cancer. Combination treatment using NIMA-related kinase 2B small interfering RNA and paclitaxel might be a novel potential therapy method for breast cancer.